⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 26, 2024Clinical pharmacology and therapyOpen Access

Short-term efficacy of anifrolumab in the treatment of patients with systemic lupus erythematosus

О. В. Бугрова Зонова Елена Владимировна Pavel Novikov В. А. Пугач V.O. Churilova N. Bulanov Sergey Moiseev

View Full Paper

Ask AI

Bookmark

Share

Abstract

Anifrolumab is a fully human monoclonal antibody that targets the type I IFN-α receptor subunit and blocks the action of the type I IFN.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Бугрова et al. (2024) studied this question.

synapsesocial.com/papers/68e686b9b6db64358760f039 https://doi.org/10.32756/0869-5490-2024-2-63-69

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TARGETING TYPE I INTERFERON SIGNALING IN SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL AND SAFETY PERSPECTIVES ON ANIFROLUMAB THERAPYClinical Trial · 2026
2Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus ErythematosusRCT · 2016 · 882 citations
3Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosusHuman Clinical Trial · 2023 · 23 citations
4Rapid resolution of fever and panniculitis after anifrolumab in a patient with systemic lupus erythematosus refractory to standard immunosuppression2025 · 1 citations
5Long-term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World CohortsRCT · 2026

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials2024
Anifrolumab Attenuates Follicular Helper T Cell Activation in Patients with Systemic Lupus Erythematosus2025
Real-world Evidence of Anifrolumab Use in Mexican Patients With Systemic Lupus Erythematosus: A Multicenter Observational Study2026
The clinical pharmacology service in Russia: a survey of clinical pharmacologistsClinical pharmacology and therapy · 2025
Enzyme replacement therapy for Fabry disease: Consensus ReportClinical pharmacology and therapy · 2025

CMore from Clinical pharmacology and therapy